Molekulargenetisches Labor
Zentrum für Nephrologie und Stoffwechsel

Interleukin 6

Das IL6-Gen kodiert ein Zytokin, welches bei der regulation von Entzündungsprozessen und bei der B-Zell-Reifung beteiligt ist. Genetische Variationen in diesem Gen werden mit der Neigung zu verschiedenen autiommun und autoinflammatorischen Prozessen in Verbindung gebracht. So zum Beispiel der Diabetes Typ 1, das Kaposi-Sarkom, Fehlbildungen der Hirngefäße und die juvenile Arthritis.

Gentests:

Klinisch Untersuchungsmethoden Familienuntersuchung
Bearbeitungszeit 5 Tage
Probentyp genomische DNS
Klinisch Untersuchungsmethoden Hochdurchsatz-Sequenzierung
Bearbeitungszeit 25 Tage
Probentyp genomische DNS
Forschung Untersuchungsmethoden Direkte Sequenzierung der proteinkodierenden Bereiche eines Gens
Bearbeitungszeit 25 Tage
Probentyp genomische DNS

Verknüpfte Erkrankungen:

Morbus Crohn mit Wachstumsstörung
IL6
Autoimmundiabetes
FOXP3
HLA-DQA1
IL6
Neigung zu arteriovenösen Fehlbildungen im Gehirn
IL6
Neigung zu Kaposi-Sarkomen
IL6
Systemische idiopathische juvenile Arthritis
IL6
LACC1
MIF

Referenzen:

1.

Kane M et. al. (2011) Successful transmission of a retrovirus depends on the commensal microbiota.

[^]
2.

Santhanam U et al. (1991) Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product.

[^]
3.

Roodman GD et al. (1992) Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone.

[^]
4.

Tosato G et al. (1988) Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6).

[^]
5.

Bowcock AM et al. (1988) The human "interferon-beta 2/hepatocyte stimulating factor/interleukin-6" gene: DNA polymorphism studies and localization to chromosome 7p21.

[^]
6.

Sehgal PB et al. (1986) Human chromosome 7 carries the beta 2 interferon gene.

[^]
7.

Zilberstein A et al. (1986) Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines.

[^]
8.

Sehgal PB et al. (1987) Rapid enhancement of beta 2-interferon/B-cell differentiation factor BSF-2 gene expression in human fibroblasts by diacylglycerols and the calcium ionophore A23187.

[^]
9.

May LT et al. (1988) Synthesis and secretion of multiple forms of beta 2-interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human fibroblasts and monocytes.

[^]
10.

Kawano M et al. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.

[^]
11.

Sutherland GR et al. (1988) Interleukin 4 is at 5q31 and interleukin 6 is at 7p15.

[^]
12.

Ferguson-Smith AC et al. (1988) Regional localization of the interferon-beta 2/B-cell stimulatory factor 2/hepatocyte stimulating factor gene to human chromosome 7p15-p21.

[^]
13.

Hirano T et al. () Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

[^]
14.

Sehgal PB et al. (1987) Human beta 2 interferon and B-cell differentiation factor BSF-2 are identical.

[^]
15.

Weissenbach J et al. (1980) Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies.

[^]
16.

Rooney M et. al. (1995) Inflammatory cytokine responses in juvenile chronic arthritis.

[^]
17.

Chung U et al. (1996) Association of interleukin-6 and hypoaldosteronism in patients with cancer.

[^]
18.

Cressman DE et al. (1996) Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice.

[^]
19.

De Benedetti F et al. (1997) Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation.

[^]
20.

Fishman D et. al. (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

[^]
21.

Fernández-Real JM et al. (2000) Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects.

[^]
22.

Ota N et al. (1999) Linkage of interleukin 6 locus to human osteopenia by sibling pair analysis.

[^]
23.

Foster CB et. al. (2000) An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus.

[^]
24.

Redwine L et al. (2000) Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans.

[^]
25.

Linker-Israeli M et al. (1999) Association of IL-6 gene alleles with systemic lupus erythematosus (SLE) and with elevated IL-6 expression.

[^]
26.

Chow D et. al. (2001) Structure of an extracellular gp130 cytokine receptor signaling complex.

[^]
27.

Scheidt-Nave C et al. (2001) Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause.

[^]
28.

Ota N et al. (2001) A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density.

[^]
29.

Venihaki M et al. (2001) Corticotropin-releasing hormone regulates IL-6 expression during inflammation.

[^]
30.

Funatsu H et al. (2002) Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema.

[^]
31.

Kovalchuk AL et al. (2002) IL-6 transgenic mouse model for extraosseous plasmacytoma.

[^]
32.

Villuendas G et al. (2002) The -597 G>A and -174 G>C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism.

[^]
33.

de Groof F et al. (2002) Acute stress response in children with meningococcal sepsis: important differences in the growth hormone/insulin-like growth factor I axis between nonsurvivors and survivors.

[^]
34.

Ferrari SL et al. (2003) Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women.

[^]
35.

Pasare C et al. (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells.

[^]
36.

Berthier MT et al. (2003) The interleukin 6-174G/C polymorphism is associated with indices of obesity in men.

[^]
37.

Powrie F et al. (2003) Immunology. Regulating the regulators.

[^]
38.

Kristiansen OP et al. (2003) Association of a functional 17beta-estradiol sensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetes in females.

[^]
39.

Chung HW et al. (2003) Association of interleukin-6 promoter variant with bone mineral density in pre-menopausal women.

[^]
40.

Boulanger MJ et al. (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.

[^]
41.

Kiecolt-Glaser JK et al. (2003) Chronic stress and age-related increases in the proinflammatory cytokine IL-6.

[^]
42.

Viereck V et al. (2003) Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.

[^]
43.

Möhlig M et al. (2004) Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes.

[^]
44.

Nemeth E et al. (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.

[^]
45.

Pawlikowska L et. al. (2004) Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic presentation of brain arteriovenous malformations.

[^]
46.

Illig T et al. (2004) Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes.

[^]
47.

Janssen SP et al. (2005) Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats.

[^]
48.

Liuzzi JP et al. (2005) Interleukin-6 regulates the zinc transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase response.

[^]
49.

Seddon JM et al. (2005) Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers.

[^]
50.

McLoughlin RM et al. (2005) IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation.

[^]
51.

Sawczenko A et. al. (2005) Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children.

[^]
52.

Chen Y et. al. (2006) Interleukin-6 involvement in brain arteriovenous malformations.

[^]
53.

Mora JR et al. (2006) Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells.

[^]
54.

Mucida D et al. (2007) Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid.

[^]
55.

Korn T et al. (2007) IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells.

[^]
56.

Lawrence T et al. (2007) Cancer. Sex, cytokines, and cancer.

[^]
57.

Naugler WE et al. (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

[^]
58.

Meng F et al. (2008) Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes.

[^]
59.

Qi L et al. (2007) Interleukin-6 genetic variability and adiposity: associations in two prospective cohorts and systematic review in 26,944 individuals.

[^]
60.

Ancrile B et al. (2007) Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis.

[^]
61.

Dai J et al. (2008) Adherence to the mediterranean diet is inversely associated with circulating interleukin-6 among middle-aged men: a twin study.

[^]
62.

Sabio G et al. (2008) A stress signaling pathway in adipose tissue regulates hepatic insulin resistance.

[^]
63.

Fairfax BP et al. (2010) An integrated expression phenotype mapping approach defines common variants in LEP, ALOX15 and CAPNS1 associated with induction of IL-6.

[^]
64.

McFarland-Mancini MM et al. (2010) Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor.

[^]
65.

Ghoreschi K et al. (2010) Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling.

[^]
66.

Xu Z et al. (2011) miR-365, a novel negative regulator of interleukin-6 gene expression, is cooperatively regulated by Sp1 and NF-kappaB.

[^]
67.

Harker JA et al. (2011) Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection.

[^]
68.

Ellingsgaard H et al. (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.

[^]
69.

Suthaus J et. al. (2012) HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice.

[^]
70.

Zenker S et al. (2014) A key regulatory role for Vav1 in controlling lipopolysaccharide endotoxemia via macrophage-derived IL-6.

[^]
71.

Zhang Q et al. (2015) Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6.

[^]
72.

Zhang C et al. (2016) CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer.

[^]
Update: 8. Mai 2019